Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics of exosomes derived from cisplatin-induced dormant A549 cells

ABSTRACT: Lung cancer is the leading cause of cancer-related deaths worldwide. Chemotherapy kills most cancer cells, however, the residual cells enter into dormant state. The dormant cancer cells can be reactivated under specific circumstances. Tumor-derived exosomes are the main mediators of tumorigenesis. We are aiming to elucidate the roles of exosomes from cisplatin-induced dormant lung cancer cells in the tumor recurrence and metastasis. We performed differential proteome in dormant A549 cell- and A549 cell-derived exosomes.

ORGANISM(S): Homo Sapiens

SUBMITTER: Juanjuan Xiang

PROVIDER: PXD037475 | iProX | Mon Oct 17 00:00:00 BST 2022

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Exosomes from cisplatin-induced dormant cancer cells facilitate the formation of premetastatic niche in bone marrow through activating glycolysis of BMSCs.

Xu Jiaqi J Feng Xiang X Yin Na N Wang Lujuan L Xie Yaohuan Y Gao Yawen Y Xiang Juanjuan J

Frontiers in oncology 20221209

<h4>Introduction</h4>Lung cancer is the leading cause of cancer-related deaths worldwide. Chemotherapy kills most cancer cells; however, residual cells enter a dormant state. The dormant cancer cells can be reactivated under specific circumstances. The "premetastatic niche" that is suitable for colonization of cancer cells is formed before the arrival of cancer cells. Tumor-derived exosomes are the main mediators of tumorigenesis. We are aiming to elucidate the roles of exosomes from cisplatin-i ...[more]

PMID: 36568212

Similar Datasets

Proteomic approach for searching of universal, tissue-specific and line-specific markers of extracellular vesicles in lung and colorectal adenocarcinoma cell lines:extracellular vesicles only

Project description:The efficiency of anticancer therapy depends heavily on the molecular features of the tumor. Since tumor-derived extracellular vesicles, including exosomes, contain proteins that are characteristic for producer cells and could be detected in biological fluids, they are of great interest for screening of predictive biomarkers. We have performed label-free mass spectrometric profiling of extracellular vesicles originated from human colon cancer cell lines Caco-2, HT-26 and HCT-116, and from lung cancer cell lines NCI-H23 and A549.

2021-09-09 | PXD020467 | Pride

Proteomic approach for searching of universal, tissue-specific and line-specific markers of extracellular vesicles in lung and colorectal adenocarcinoma cell lines: whole cell lysate vs. extracellular vesicles

2021-09-09 | PXD020454 | Pride

Homo sapiens

Project description:miRNA expression of exosomes derived from lung cancer cells A549 and cisplatin (DDP) resistant lung cancer cells A549/DDP

| PRJNA338941 | ENA

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

Project description:Residual tumor cells which remain dormant after MYC inactivation in a primary MYC-HCC derived cell line.

2024-08-06 | GSE242745 | GEO

Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model

Project description:Gene expression profiling of disseminated tumor cells in lung, lung metastatses and residual tumor cells in the MMTV-PyMT breast cancer model. Profiling gene expression change between disseminated tumor cells, lung metastases and residual tumor cells from the MMTV-PyMT breast cancer model.

2013-01-18 | E-GEOD-43566 | biostudies-arrayexpress

Autocrine IGF1 signaling mediates pancreatic tumor cell dormancy in the absence of oncogenic drivers

Project description:Mutant KRAS and c-MYC are oncogenic drivers and rational therapeutic targets for the treatment of pancreatic cancer. While tumor growth and homeostasis is largely dependent on these oncogenes, a few residual cancer cells are able to survive the ablation of mutant KRAS and c-MYC. By performing a genome-wide gene expression analysis of in vivo-derived bulk tumor cells and residual cancer cells lacking the expression of mutant KRAS or c-MYC, we have identified an increase in autocrine IGF1/AKT signaling as a common survival mechanism in dormant cancer cells. The pharmacological inhibition of IGF-1R reduced residual disease burden and cancer recurrence, suggesting this molecular pathway is crucial for the survival of cancer cells in the absence of the primary oncogenic drivers.

2017-02-09 | GSE93946 | GEO

miRNA expression of exosomes derived from lung cancer cells A549 and cisplatin (DDP) resistant lung cancer cells A549/DDP

Project description:To investigate the difference of miRNA expression in exosomes derived from A549 cells and its DDP-resistant cell strain A549/DDP, we have employed miRNA microarray expression to discover the difference expression of miRNAs in exosomes derived from A549 and A549/DDP. We conducted RT-qPCR to examine the expression levels of top differential expressed miRNAs, namely, miR-197-5p, miR-4443, miR-642a-3p, miR-27b-3p and miR-100-5p, confirming low variability between two methods. The A549/DDP was established from A549 in our laboratory, by exposing A549 to gradually increasing DDP concentrations, until the final concentration at 1Î¼g/ml. To avoid the influence of drug to the A549/DDP cells, they were cultured in a drug-free medium for at least two weeks before gene expression analysis. After being incubated for 48-72h, the culture medium of cells was harvested. Exosomes were isolated by ultracentrifugation. And miRNA expression of exosomes derived from A549 and A549/DDP was then analzyed.

2016-08-16 | E-GEOD-85604 | biostudies-arrayexpress

RNA Sequencing Analysis of Human Non-Small Cell Lung Cancer Cell Line A549 in Dormancy Induction and Osteoclast-Activated States

Project description:When lung adenocarcinoma cells metastasize to the bone microenvironment, they often enter a dormant state. These dormant cells can be reactivated after bone microenvironment remodeling and reemerge as metastatic disease, posing challenges for the treatment and prognosis of lung adenocarcinoma. In the bone microenvironment, it is primarily osteoclasts that activate dormant lung adenocarcinoma cells. However, the specific mechanism by which osteoclasts contact dormant lung adenocarcinoma cells and promote their proliferation remains unclear. In this experiment, dormant lung adenocarcinoma cells were induced through in vitro culture and treated with osteoclast-conditioned medium for 24 hours to obtain osteoclast-activated lung adenocarcinoma cells. RNA-seq was performed on both dormant and activated lung adenocarcinoma cells to analyze the specific mechanism of the transition from dormancy to activation in lung adenocarcinoma cells following osteoclast interaction.

2025-04-30 | GSE289262 | GEO

Microarray analysis of exosomal miRNAs from different liver cancer cells

Project description:To explore how tumor-derived exosomes activate fibroblasts and foster lung metastasis of liver cancer. MiRNAs encapsulated in exosomes are abundant and play an important role in cell-cell communication. Therefore, we hypothesized that tumor-derived exosomal miRNAs mediate fibroblasts activation. To identify the specific miRNAs involved, we conducted microarrays to generate miRNAs profiles of exosomes derived from the four liver cancer cell lines with different migration and invasion abilities. CSQT-2 and HCC-LM3 cells were high metastatic cancer cells, versus to HepG2 and MHCC-97L cells. We divided them into the following groups: CSQT-2 versus HepG2 (with different origins), HCC-LM3 versus MHCC-97L (with the same origin) and compared the up-regulated miRNAs in both two high-metastatic cancer cells-derived exosomes. Then, these up-regulated miRNAs were subjected to validation to define the most important exosomal miRNAs in regulating fibroblast activation and contributing to lung metastasis of liver cancer.

2017-11-03 | GSE106452 | GEO

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in NSCLC (scRNA-Seq)

Project description:Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.

2024-02-29 | GSE260499 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data